In ₹ Crore except Per Share Latest Annual	ORIENTCEM FY26	AMBUJACEM FY26	ULTRACEMCO FY26	DALBHARAT FY26	Peer Average
Valuation — at last close
P/E	◆ 6.99×	18.52×	40.25×	23.18×	27.32× -74%
P/B	◆ 1.10×	1.48×	4.30×	1.49×	2.42× -55%
EV/EBITDA	◆ 4.36×	15.18×	20.63×	9.18×	15.00× -71%
Market Cap	₹2,361 Cr	₹87,675 Cr	₹3.29L Cr	₹26,750 Cr	₹1.48L Cr -98%
Growth
Revenue CAGR 3Y	-1.67%	1.45%	◆ 11.86%	3.02%	5.44% -131%
Revenue CAGR 5Y	3.75%	7.02%	◆ 14.63%	7.07%	9.57% -61%
Net Income CAGR 3Y	◆ 40.09%	23.07%	17.30%	2.35%	14.24% +182%
Revenue YoY (latest Q)	-12.17%	0.25%	◆ 18.81%	4.27%	7.78% -256%
Net Income YoY (latest Q)	-34.81%	-89.75%	◆ 21.28%	-185.77%	-84.75% +59%
Profitability
EBITDA Margin	19.53%	16.08%	19.23%	◆ 20.83%	18.71% +4%
Net Income Margin	12.09%	◆ 13.87%	9.25%	7.82%	10.31% +17%
Return on Common Equity	◆ 17.08%	8.38%	11.08%	6.44%	8.63% +98%
Return on Capital Employed	◆ 13.15%	4.13%	11.85%	6.59%	7.52% +75%
Return on Assets	◆ 11.38%	6.61%	5.95%	3.64%	5.40% +111%
Credit & Quality
Total Debt/Equity	0.02×	◆ 0.00×	0.28×	0.37×	0.22× -91%
Interest Coverage	◆ 24.70×	13.28×	6.61×	3.61×	7.83× +215%
Scale — latest FY
Revenue / Total Income	₹2,793 Cr	₹40,656 Cr	₹88,512 Cr	₹14,804 Cr	₹47,990 Cr -94%
Net Income	₹338 Cr	₹5,637 Cr	₹8,188 Cr	₹1,157 Cr	₹4,994 Cr -93%
Total Assets	₹3,133 Cr	₹89,607 Cr	₹1.41L Cr	₹33,312 Cr	₹88,098 Cr -96%
EPS	₹16.44	₹19.15	₹277.62	₹60.73	₹119.17 -86%
Book Value per Share	₹104.44	₹240.1	₹2,600.23	₹946.26	₹1,262.2 -92%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.